Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
Active, not recruiting · NCT03914300 · Registry updated 2026-07-31Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thyroid Cancer, Papillary, adenocarcinoma, carcinoma, differentiated thyroid carcinoma, endocrine system disorder, epithelial neoplasm, follicular variant thyroid gland papillary carcinoma, malignant endocrine neoplasm, neoplasm, papillary adenocarcinoma, poorly differentiated thyroid gland carcinoma, tall cell variant thyroid gland papillary carcinoma, thyroid gland disorder, thyroid gland follicular carcinoma, thyroid gland papillary carcinoma, thyroid tumor | Active, not recruiting | Phase 2 | 2026-07-31 | NCT03914300 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
33 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.